FATE - Fate Therapeutics Inc
Fate Therapeutics Inc Logo

FATE - Fate Therapeutics Inc

https://www.fatetherapeutics.com
Hold Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
As of 2025-09-10 (Snapshot)

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally. The company is headquartered in San Diego, California.

52W High
$4.20
52W Low
$0.66
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
2.22
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-2.59
EV/Revenue (<3 favorable)
20.39
P/S (TTM) (<3 favorable)
13.75
P/B (<3 favorable)
0.45
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
1.71%
Institutions (25–75% balanced)
78.68%
Shares Outstanding
115,330,000
Float
100,797,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
8,470,000
Gross Profit (TTM)
-106,806,000
EPS (TTM)
-1.46
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-19.39%
ROE (TTM) (>15% strong)
-0.52%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-0.72
Momentum
Bearish momentum
Value
-0.0326
Previous
-0.0243
Trend
Falling
Signal Cross
No cross
As of
Sep. 04, 2025